What is the specific therapeutic effect of Opicapone?

Opicapone is a new, long-acting, selective peripheral catechol-O-methyltransferase (COMT) inhibitor, mainly used to treat the "switch phenomenon" that occurs in patients with Parkinson's disease during the use of levodopa (Levodopa) - that is, the fluctuation of motor symptoms, especially the prolonged "off period". The addition of Opicapone can stabilize the peripheral levodopa concentration, thereby enhancing its central efficacy, allowing patients to have a longer "on time" during treatment and reducing the inconvenience and pain caused by the "off time".

In a number of key clinical studies, Opicapone has shown good efficacy and tolerability. The most representative studies areBIPARK-1 and BIPARK-2. These two randomized, double-blind, placebo-controlled, phase 3 clinical trials evaluated opicapone as an adjunct to levodopa. In the BIPARK-1 study, patients took 50 mg of Opicapone once a day. Compared with the placebo group, the average "off period" was reduced by nearly 1 hour, and the extended "on period" was not accompanied by an aggravation of dyskinesia, suggesting that it can prolong the action time of levodopa without increasing the patient's risk of motor side effects. The BIPARK-2 study further confirmed this conclusion. The results showed that opicapone was significantly better than placebo, and its efficacy was equivalent to that of the existing COMT inhibitor Tolcapone, but its safety profile was better and it did not require frequent monitoring of liver function.

Opicapone has several therapeutic advantages compared with earlierCOMT inhibitors. First, it has stronger peripheral selectivity, which can effectively block the metabolism of levodopa by peripheral COMT, increase its concentration across the blood-brain barrier, and maintain a more stable level of dopamine in the brain. Secondly, its long-acting mechanism of action allows patients to take the medication only once a day, effectively improving compliance and avoiding life disruption caused by multiple medication doses. In addition, the risk of hepatotoxicity with opicapone is much lower than that of tolcapone, and it does not require co-administration with levodopa like entacapone.

In real-world use, the therapeutic effect of Opicapone in patients with Parkinson's disease has also been widely recognized by doctors and patients. Especially in the middle and late stages of the disease, patients often experience fluctuations in efficacy due to levodopa treatment. At this time, the addition of Opicapone can significantly reduce the "off period", improve the quality of life, and improve the ability to perform daily activities. Some studies have found that Opicapone can start to take effect within a few days, and some patients can experience an extension of their "onset" time within the first week.

However, although Opicapone is effective, attention should be paid to the possible mild side effects that some patients may experience, such as constipation, insomnia, dry mouth, and hallucinations. This is especially true in elderly patients or those who are treated with multiple Parkinson's drugs. In addition, because it enhances the effect of levodopa by inhibiting peripheral COMT, it may cause levodopa-related adverse reactions in some patients, such as dyskinesia or hypotension. Therefore, it is necessary to closely monitor and adjust the original levodopa dose in the early stage of dosing.

In general, as a potential auxiliary drug in the management of the "switch phenomenon" of Parkinson's disease, Opicapone not only has significant efficacy, but also can reduce the "off period" and prolong the "on period" of patients. It is also safe and convenient to take. It is an important breakthrough in the current field of COMT inhibitor treatment.

Reference materials:https://www.ongentys.com/